BioSpace News Archive

Soliton, Inc., a medical device company with a novel and proprietary platform technology, announced that the company’s Rapid Acoustic Pulse device received the Best New Technology Award from the Aesthetic Industry Association.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming virtual investor conferences:

Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit intended for the qualitative detection of immunoglobulin G (IgG) antibodies to SARS-CoV-2 in human serum or plasma.

Restorative Therapies, Inc – the leading provider of innovative, integrated therapeutic medical devices that are the standard of care in rehabilitation therapy for many neurological conditions – announced today the launch of Xcite2.

Centene Corporation (NYSE: CNC) (“Centene” or the “Company”) announced the results of its previously announced tender offer (the “Tender Offer”) to purchase for cash any and all of its outstanding $2,200,000,000 aggregate principal amount of 4.75% Senior Notes due 2025 (the “2025 Notes”) from each registered holder of the 2025 Notes (the “Holders”),

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will present an overview of the Company at the following upcoming investor conferences:

Particle therapy or radiation therapy involves use of X-rays and high energy rays that destroy the cancerous cells in the tumor or target area.

Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced positive safety and efficacy results from a planned interim analysis of PSOARING 3, its long-term, open-label safety study that, along with previously reported PSOARING 1 and PSOARING 2 pivotal efficacy trials,

Next Generation Sequencing or NGS is an outstanding technology that arranges massive DNA strands through enormous parallelization.

Digital therapeutics (DTx) is tasked with the delivery of therapeutic interventions that are based on evidence.